Skip to main content

Table 4 HLA-DQ genotype and serum IL-2 after gluten

From: Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease

Genotype group, participants (n) Serum IL-2 concentrations, median (interquartile range) pg/ml Responders participants, n (%)
2 h 4 h 6 h Maximum††
1. DQ2.5 positive (266) 2.2 (< 0.5–8.6) 3.2 (0.6–10.7) 1.2 (< 0.5–4.5) 4.6 (0.8–13.1) 217 (82%)
2. DQ2.5 negative‡‡ (29) < 0.5 (< 0.5–1.2) 0.6 (< 0.5–2.9) < 0.5 (< 0.5–1.1) 0.6 (< 0.5–3.6) 17 (52%)
3. DQ2.5, 2.5 (34) 2.7 (0.8–8.0) 3.7 (1.3–9.4) 1.6 (0.6–4.9) 5.9 (1.8–10.8) 29 (85%)
4. DQ2.5, 2.2 (56) 5.5 (2.5–12.9) 9.0 (2.6–22.9) 3.7 (0.9–7.0) 10.2 (4.7–24.5) 52 (93%)
5. DQ2.5, 7 (15) 0.8 (< 0.5–7.4) 1.8 (< 0.5–5.0) 0.8 (< 0.5–1.4) 1.8 (< 0.5–9.0) 11 (73%)
6. DQ2.5, 8 (36) 1.1 (< 0.5–6.7) 2.4 (< 0.5–5.7) 0.9 (< 0.5–2.8) 2.7 (0.6–8.5) 28 (78%)
7. DQ2.5trans (18) 1.5 (0.7–8.2) 3.3 (0.9–12.5) 1.5 (0.6–6.9) 3.3 (0.9–12.5) 16 (89%)
8. DQ2.5cis, X (107) 1.4 (< 0.5–6.3) 1.9 (< 0.5–8.1) 0.8 (< 0.5–3.0) 2.5 (0.6–10.4) 81 (76%)
  1. HLA-DQA and DQB alleles for the following genotype groups: 1. DQA1*05 and DQB1*02 both present; 2. absent either or both DQA1*05 and DQB1*02; 3; homozygous both DQA1*05 and DQB1*02; 4. DQA1*02,05, and DQB1*02 homozygous; 5. DQA1*05 homozygous and DQB1*02,03; 6. DQA1*03,05 and DQB1*02,03; 7. DQA1*02,05 and DQB1*02,03; 8. Other patients with DQA1*05 and DQB1*02
  2. Responders defined by maximum serum IL-2 concentration at least 0.5 pg/ml
  3. ††Mann-Whitney test false discovery rate-adjusted p values for six comparisons were significant for the presence of DQ2.5 (group 1 vs 2), p = 0.004; DQB1*02 gene dose (groups 5, 6, 7 and 8 vs 3 and 4), p = 0.0009; p values were not significant for DQA1*05 gene dose (groups 4, 6, 7 and 8 vs 3 and 5), DQ2.5 homozygotes vs DQ2.5, 2.2 (group 3 vs 4), DQ2.5cis, X vs DQ2.5trans (group 7 vs 8) and for DQ2.5,8 vs DQ2.5cis, X (group 7 vs 8)
  4. ‡‡See Table S8 for genotypes, symptoms and IL-2 responses of HLA-DQ2.5-negative patients